NCT06926751View on ClinicalTrials.gov

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

September 1, 2027

Conditions
Solid TumorsChildrenAdolescentChemotherapy Induced Neutropenia
Interventions
DRUG

Telpegfilgrastim Injection

subcutaneous injections of Telpegfilgrastim (33 μg/kg, single dose) 24 hours after each chemotherapy cycle

DRUG

filgrastim

subcutaneous injections of Filgrastim (5 μg/kg/day, multiple doses) 24 hours after each chemotherapy cycle

Trial Locations (1)

Unknown

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER